Human Immunodeficiency Virus (hiv) Patents (Class 514/3.8)
-
Publication number: 20130143795Abstract: The invention relates to a method of treating HIV or AIDS comprising administering a composition comprising a polypeptide comprising LKKTETQ (SEQ ID NO: 1) or a variant thereof, or administering a composition comprising a peptidomimetic of a polypeptide comprising amino acid sequence LKKTETQ (SEQ ID NO: 1) or a variant thereof.Type: ApplicationFiled: July 14, 2011Publication date: June 6, 2013Applicant: Adistem Ltd.Inventor: Vasilis Paspaliaris
-
Publication number: 20130130971Abstract: The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g.Type: ApplicationFiled: April 1, 2011Publication date: May 23, 2013Applicant: CENTRO DE INGENIERÁA GENÁTICA Y BIOTECNOLOGÁAInventors: Celia Berta Fernandez Ortega, Anna Caridys Ramírez Suárez, Dionne Casillas Casanova, Taimi Emelia Paneque Guerrero, Raimundo Ubieta Gómez, Marta Dubed Echevarria, Leonor Margarita Navea Leyva, Lila Rosa Castellanos Serra, Carlos Antonio Duarte Cano, Viviana Falcón Cama, Osvaldo Reyes Acosta
-
Patent number: 8445431Abstract: Ligands having a metal binding domain and a targeting domain are provided. The ligands can be used to target, inhibit, and catalytically degrade or inactivate a desired target. Methods of treating a disease or condition using the ligands are also provided.Type: GrantFiled: June 1, 2005Date of Patent: May 21, 2013Assignee: The Ohio State UniversityInventors: James A. Cowan, Yan Jin, Seth Bradford, Nikhil Gokhale, Ada Cowan, Chun-An Chen
-
Publication number: 20130108653Abstract: The present invention relates to a new class of virus fusion inhibitors or virus entry inhibitors. More specifically the present invention relates to bivalent molecules that are pre-fusion inhibitors of viruses that makes use of the type (1) fusion mechanism belonging to the groups consisting of Othomyxoviridae, Paramyxoviridae, Retroviridae, Filoviridae and Coronaviridae, in particular HIV. The bivalent molecules of the present invention are molecules that comprise a first part capable of mimicking the function of a mammalian cell receptor, and a second part capable of binding to a virus, preferably HIV, resulting in the neutralization of the virus which is thus rendered harmless. Further, the present invention relates to compositions comprising the pre-fusion inhibitors, as well as to methods for obtaining the pre-fusion inhibitors and the use of the pre-fusion inhibitors.Type: ApplicationFiled: December 22, 2010Publication date: May 2, 2013Inventors: Shervin Bahrami, Martin Tolstrup, Mogens Duch Ryttergmrd, Finn Skou Pedersen, Lars Jørgen Ostergaard
-
Publication number: 20130109614Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.Type: ApplicationFiled: June 12, 2012Publication date: May 2, 2013Inventors: Jya-Wei Cheng, Kuo-Chun Huang, Hsi-Tsung Cheng, Hui-Yuan Yu
-
Publication number: 20130109619Abstract: A peptide or peptidomimetic comprising an amino acid sequence based on conserved regions of IL10 or IFN-gamma receptor sequences, and related compounds and compositions, as well as methods for the use thereof to inhibit cytokine signaling.Type: ApplicationFiled: May 11, 2011Publication date: May 2, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya I. Tarasova, Giorgio Trinchieri, Howard A. Young, C. Andrew Stewart, Marco A. Cardone, Alan O. Perantoni
-
Patent number: 8431530Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: GrantFiled: May 20, 2010Date of Patent: April 30, 2013Assignee: Morehouse School of MedicineInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Publication number: 20130096051Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity.Type: ApplicationFiled: April 11, 2011Publication date: April 18, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: David Markovitz, Michael Swanson, Irwin Goldstein, Harry Winter
-
Patent number: 8415399Abstract: An infection inhibitor of retrovirus, particularly human immunodeficiency virus, comprising, as an active ingredient, at least one compound selected from the group consisting of a compound represented by the formula (I) (GGA) or a salt thereof, a compound represented by the formula (II) (NIK-333) or a salt thereof, and derivatives thereof.Type: GrantFiled: September 27, 2011Date of Patent: April 9, 2013Assignees: Nagasaki University, Kowa Company, Ltd.Inventors: Yoshinao Kubo, Haruka Kamiyama
-
Publication number: 20130085097Abstract: Methods and compositions for preventing viral infection are disclosed. Compositions containing papillomavirus VLPs or capsomeres are used, alone or in combination with other agents, as microbicides that substantially block papillomavirus binding receptors on the surface or vicinity of cells in a tissue to be treated with the composition. The invention can be used to inhibit papillomavirus infection or infection by another virus that utilizes the same binding receptors during the infection process.Type: ApplicationFiled: March 22, 2011Publication date: April 4, 2013Applicant: UNIVERSITY OF ROCHESTERInventor: William Bonnez
-
Publication number: 20130084327Abstract: The invention provides an isolated nucleic acid encoding a TRIM-cyclophilin A fusion sequence encoding a TRIMcyp fusion protein which is active as an anti-viral agent, and in particular an anti-HIV-1 agent. The invention provides for a nucleic acid encoding a polypeptide having both TRIM activity and cyclophilin activity. The invention provides for an isolated polynucleotide encoding a TRIM-cyclophilin fusion protein, or variants thereof retaining the TRIM and cyclophilin activities. The invention provides for compositions thereof, antibodies that specifically bind thereto, and vectors and host cells comprising the nucleic acid or polypeptide. In addition, the invention provides for methods for treating or preventing viral infection, or reducing viral load in a subject comprising administering the nucleic acid, polypeptide, vector, or composition to the subject in an amount effective to treat or prevent the viral infection.Type: ApplicationFiled: December 20, 2011Publication date: April 4, 2013Inventors: Jeremy Luban, David Sayah
-
Publication number: 20130072421Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.Type: ApplicationFiled: January 13, 2011Publication date: March 21, 2013Applicant: CURNA, INCInventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito, Belinda De Leon
-
Publication number: 20130065819Abstract: Described are methods and compositions for preventing and/or treating HIV infection, as well as in vitro and in vivo methods of inhibiting HIV replication, inhibiting HIV viral transcription, inhibiting the viral Tat protein, and inhibiting HIV LTR expression. The methods involve administering a Target of Egr1 (TOE1) polypeptide, fragment or deletion mutant thereof, either to a subject in need of treatment or to a cell infected with an HIV virus. Compositions may comprise the described polypeptide, or an encoding polynucleotide thereof.Type: ApplicationFiled: March 4, 2011Publication date: March 14, 2013Inventors: Ian De Belle, Sabina Sperandio
-
Patent number: 8394764Abstract: An isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, as well as an isolated and purified nucleic acid molecule that encodes a polypeptide comprising at least eight contiguous amino acids of SEQ ID NO: 3, wherein the at least eight contiguous amino acids have anti-viral activity, and, when the at least eight contiguous amino acids comprise amino acids 1-121 of SEQ ID NO: 3, the at least eight contiguous amino acids have been rendered glycosylation-resistant, a vector comprising such an isolated and purified nucleic acid molecule, a host cell comprising the nucleic acid molecule, optionally in the form of a vector, a method of producing an anti-viral polypeptide or conjugate thereof, the anti-viral polypeptide itself, a conjugate or fusion protein comprising the anti-viral polypeptide, and compositions comprising an effective amount of the anti-viralType: GrantFiled: February 7, 2011Date of Patent: March 12, 2013Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Michael R. Boyd, Toshiyuki Mori, Barry R. O'Keefe
-
Publication number: 20130059776Abstract: Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus.Type: ApplicationFiled: October 31, 2012Publication date: March 7, 2013Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
-
Publication number: 20130053303Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.Type: ApplicationFiled: October 5, 2012Publication date: February 28, 2013Applicant: Onyx Therapeutics, Inc.Inventor: Onyx Therapeutics, Inc.
-
Publication number: 20130053306Abstract: There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group of materials, including recombinant human histone H1 or at least an H1 subtype or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity.Type: ApplicationFiled: March 30, 2012Publication date: February 28, 2013Inventor: Reiner Class
-
Publication number: 20130039885Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: ApplicationFiled: June 19, 2012Publication date: February 14, 2013Applicant: NEW YORK UNIVERSITYInventors: Victor J. TORRES, Derya UNUTMAZ, Francis ALONZO, III
-
Publication number: 20130034519Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 13, 2012Publication date: February 7, 2013Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
-
Publication number: 20130029902Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.Type: ApplicationFiled: July 3, 2008Publication date: January 31, 2013Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
-
Publication number: 20130023463Abstract: A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.Type: ApplicationFiled: April 19, 2012Publication date: January 24, 2013Applicant: ABBOTT LABORATORIESInventors: Charles A. Flentge, Hui-Ju Chen, David A. DeGoey, William J. Flosi, David J. Grampovnik, Peggy P. Huang, Dale J. Kempf, Larry L. Klein, Allan C. Krueger, Darold L. Madigan, John T. Randolph, Minghua Sun, Ming C. Yeung, Chen Zhao
-
Publication number: 20130004458Abstract: Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.Type: ApplicationFiled: September 14, 2012Publication date: January 3, 2013Applicant: NEW YORK BLOOD CENTER, INC.Inventors: Asim Kumar Debnath, Hongtao Zhang, Francesca Curreli
-
Publication number: 20120328568Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.Type: ApplicationFiled: February 11, 2011Publication date: December 27, 2012Applicant: EMORY UNIVERSITYInventors: Richard D Cummings, Sean R. Stowell, Connie Arthur
-
Publication number: 20120329705Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: June 8, 2012Publication date: December 27, 2012Inventors: Mark S. Smyth, Guy J. Laidig
-
Patent number: 8334255Abstract: A compound of the formula X1-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X1-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.Type: GrantFiled: December 4, 2007Date of Patent: December 18, 2012Assignees: Thomas Jefferson University, OyaGen Inc.Inventors: Hui Zhang, Harold C. Smith
-
Patent number: 8329658Abstract: This invention provides compounds of general formula (I): wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus and/or human immunodeficiency virus.Type: GrantFiled: October 2, 2006Date of Patent: December 11, 2012Assignee: Scynexis, Inc.Inventors: David Renwick Houck, Keqiang Li
-
Publication number: 20120295841Abstract: There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.Type: ApplicationFiled: February 9, 2011Publication date: November 22, 2012Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Christine Janet Martin
-
Publication number: 20120289459Abstract: New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8.Type: ApplicationFiled: October 20, 2008Publication date: November 15, 2012Applicant: ALTERNATIVE GENE EXPRESSION, S.L.Inventors: Covadonga Alonso Martí, Bruno Hernaez De La Plaza, José Angel Martinez Escribano
-
Publication number: 20120282218Abstract: New chiral and achiral oxy-substituted cyclopentyl pyridinone diketocarboxamides and their derivatives and methods for their preparations are disclosed. The compounds include tautomers, regioisomers and geometric isomers. These complex carboxamides are designed as inhibitors of HIV replication through inhibition of HIV integrase. The compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as pharmaceutically acceptable salts, with pharmaceutically acceptable carriers, used alone or in combination with antivirals, immunomodulators, antibiotics, vaccines, and other therapeutic agents, especially other anti-HIV compounds (including other anti-HIV integrase agents), which can be used to create combination anti-HIV cocktails. Methods of treating AIDS and ARC and methods of treating or preventing infection by HIV are also described.Type: ApplicationFiled: December 7, 2010Publication date: November 8, 2012Applicant: University of Georgia Research Foundation Inc.Inventors: Vasu Nair, Maurice O. Okello, Abdumalik A. Nishonov, Sanjaykumar Mishra
-
Publication number: 20120277146Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: March 2, 2012Publication date: November 1, 2012Applicant: ONYX PHARMACEUTICALS INC.Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser
-
Publication number: 20120269766Abstract: The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-H? function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-H's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.Type: ApplicationFiled: October 12, 2010Publication date: October 25, 2012Applicant: Yale UniversityInventors: David Spiegel, Christopher Parker
-
Publication number: 20120270774Abstract: The present invention relates to backbone cyclized CD-4 mimetics and to compositions and methods comprising them for preventing and treating viral infection. In particular, the present invention relates to orally bio-available compounds and formulations for prevention and treatment of human HIV-1 infection.Type: ApplicationFiled: August 29, 2010Publication date: October 25, 2012Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem LTdInventors: Chaim Gilon, Amnon Hoffman, Moshe Kotler, Mattan Hurevich, Salim Joubran, Avi Swed
-
Publication number: 20120263782Abstract: A method for treating latent HIV infection is disclosed. The method includes administering to a subject in need of such treatment an effective amount of an anti-I?B? agent, an anti-I?B? agent or both; and administering to the subject an effective amount of an antiviral agent. A pharmaceutical composition for treating latent HIV infection is also disclosed.Type: ApplicationFiled: May 29, 2012Publication date: October 18, 2012Applicant: CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTERInventors: STEVEN L. ZEICHNER, GUERAU FERNANDEZ
-
Publication number: 20120264676Abstract: An antioxidant compound is disclosed, along with pharmaceutical compositions and methods of treatment which utilize said compound. The compound is characterized by a peptide including at least three amino acid residues of which at least two are cysteine residues, and a first hydrophobic or non-charged moiety being attached to an amino terminal of the peptide via a first bond and a second hydrophobic or non-charged moiety being attached to a carboxy terminal of the peptide via a second bond, as described herein. Cleavage of the peptide by an intracellular peptidase results in generation of a plurality of antioxidant species, each including one of the cysteine residues, thereby providing for a plurality of different antioxidant species acting in synergy in exerting antioxidation.Type: ApplicationFiled: April 25, 2012Publication date: October 18, 2012Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Daphne ATLAS
-
Publication number: 20120258908Abstract: The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention.Type: ApplicationFiled: February 1, 2012Publication date: October 11, 2012Applicant: KINETA TWO, LLCInventors: SHAWN P. IADONATO, CHARLES L. MAGNESS, MARK BRANUM, MARALEE MCVEAN, CHRISTINA SCHERER
-
Publication number: 20120251581Abstract: There is provided inter alia a compound of formula (I): for use in treatment of viral infection or as an immunosuppressant.Type: ApplicationFiled: March 29, 2012Publication date: October 4, 2012Inventors: Matthew Alan Gregory, Steven James Moss, Barrie Wilkinson
-
Publication number: 20120245081Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.Type: ApplicationFiled: August 15, 2011Publication date: September 27, 2012Applicant: Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Ramachandran Murali, Akihiro Hasegawa
-
Publication number: 20120237501Abstract: Anti-HIV peptides and methods of use are provided. In particular, these HIV inhibitory peptides are discovered based on the Antimicrobial Peptide Database.Type: ApplicationFiled: October 19, 2010Publication date: September 20, 2012Inventor: Guangshun Wang
-
Patent number: 8268778Abstract: GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving a -GBV-C NS5A peptide or polypeptide for inhibiting and treating HIV infections.Type: GrantFiled: March 20, 2008Date of Patent: September 18, 2012Assignee: University of Iowa Research FoundationInventors: James McLinden, Jinhua Xiang, Jack T. Stapleton
-
Publication number: 20120225808Abstract: The present invention relates to a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide according to the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and thus functions as a TRPV1 activity modulator. Therefore, the present Maillard peptide can be used as a pharmaceutical composition for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic/allergic/inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: ApplicationFiled: November 8, 2010Publication date: September 6, 2012Applicants: SNU R&DB FOUNDATION, KOREA FOOD RESEARCH INSTITUTEInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Publication number: 20120225083Abstract: The invention is directed to polypeptides and polypeptide fragments from HIV-1 envelope (Env) proteins following the characterization of Env structures from environments where HIV isolates expose conserved neutralization-sensitive Env structures. There is provided a polypeptide being all or a fragment of an HIV-1 envelope protein from a transmission strain of HIV-1, the polypeptide having neutralization sensitive epitopes that are accessible.Type: ApplicationFiled: September 16, 2009Publication date: September 6, 2012Applicants: THE UNIVERSITY OF MELBOURNE, THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH, NEWSOUTH INNOVATIONS PTY LIMITEDInventors: Damian Purcell, Robert Center, Sharmila Mohana Rama Reddy, Anthony Dominic Kelleher, David Albert Cooper, Paul Rene Gorry, Jasminka Sterjovski
-
Publication number: 20120214731Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.Type: ApplicationFiled: January 19, 2012Publication date: August 23, 2012Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
-
Publication number: 20120213732Abstract: This invention relates to targeted delivery of anti-viral compounds through protein bioconjugation. More particularly, it relates to an anti-viral compound conjugated to a protein, such as hemoglobin and to a method of treating a viral infection using said conjugate. The invention also provides a method of targeted drug delivery of an anti-viral nucleoside analogue to macrophages, cells comprising a hemoglobin receptor and to CD163 bearing cells.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: Therapure Biopharma Inc.Inventors: J. Gordon Adamson, David Bell, Nancy Ng, Petrus Biessels
-
Patent number: 8247613Abstract: The present invention provides methods and compositions useful for the elimination of latent HIV reservoirs that persist despite HAART. The methods and compositions overcome this latent barrier by inducing the replication of HIV in latently infected T cells while preventing the spread of the newly produced virions to uninfected cells by providing HAART simultaneously. Compositions of the invention comprise an activator of latent HIV expression, such as prostratin, and an inhibitor of histone deacetylase, such as TSA. A surprising finding of this invention is that the inhibitor of the histone deacetylase synergizes the effect of prostratin thus, allowing administering to a patient a lower, non-toxic dose of prostratin.Type: GrantFiled: April 17, 2007Date of Patent: August 21, 2012Assignee: The J. David Gladstone InstitutesInventors: Samuel A. F. Williams, Warner C. Greene
-
Publication number: 20120208745Abstract: We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments.Type: ApplicationFiled: April 19, 2012Publication date: August 16, 2012Inventor: Deirdre McIntosh
-
Patent number: 8236756Abstract: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.Type: GrantFiled: May 10, 2004Date of Patent: August 7, 2012Assignees: Consejo Superior de Investigaciones Clentificas (CSIC), K.U. Leuven Research & DevelopmentInventors: Jan Balzarini, Maria José Camarasa Ríus, Sonsoles Velázquez Díaz
-
Publication number: 20120177676Abstract: The present invention relates to HIV-1 gp41-binding single-chain 3-stranded alpha-helical coiled coil molecules, denoted “Alphabodies”, nucleic acids encoding said Alphabodies, host cells comprising said nucleic acids, as well as pharmaceutical compositions comprising said Alphabodies, and methods for the treatment, prevention and diagnosis of HIV infection using said Alphabodies.Type: ApplicationFiled: July 7, 2010Publication date: July 12, 2012Applicant: Complix NVInventors: Johan Desmet, Ignace Joseph Isabella Lasters, Sophie Vanwetswinkel
-
Publication number: 20120172286Abstract: A previously unrecognized fundamental property of ?1PI is to regulate the phenotypic composition of circulating and tissue-associated cells derived from hematopoietic stem cells. The present invention comprises screening for various unmodified and modified ?1PI's which are useful in the treatment of abnormalities in the number of cells of myeloid or lymphoid lineage that are associated with HW-1 infection, microbial infection, leukemia, solid tumor cancers, atherosclerosis, autoimmunity, stem cell transplantation, organ transplantation, and other diseases affected by cells of the immune system. The interaction of ?1PI with its receptors, HLECS and LRP, influences the level of cells of different lineages. Genetic and proteolytic modification of ?1PI is used to target these receptors to increase or decrease specific cell populations, as needed, in the various disease states.Type: ApplicationFiled: November 22, 2011Publication date: July 5, 2012Applicant: Institute for Human Genetics and BiochemistryInventor: Cynthia L. Bristow
-
Publication number: 20120165250Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-I entry inhibitor candidate.Type: ApplicationFiled: June 24, 2010Publication date: June 28, 2012Inventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
-
Publication number: 20120165248Abstract: Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.Type: ApplicationFiled: October 12, 2011Publication date: June 28, 2012Applicant: fiRST S.r.l.Inventors: Umberto Benatti, Giorgio Brandi, Enrico Garaci, Mauro Magnani, Enrico Millo, Anna Taresa Palamara, Luigia Rossi